Koo,

I highly recommend you look at Tables 2, 3 and 4 in the reference I previously shared with you. These tables provide much more detail and context than either of your previous posts citing http://www.thennt.com/home-nnt/ or the google search for "what is the nnt for lipitor?". The tables in the reference break down the absolute risk reduction and NNT elicited by LDL-C lowering by: baseline LDL-C level, baseline absolute risk of cardiovascular disease, magnitude of LDL-C reduction and duration of LDL-C reduction. 

From your http://www.thennt.com/home-nnt/ examples:

http://www.thennt.com/nnt/statins-for-acute-coronary-syndrome/

This study only reported results for patients that were followed for 4 months after initiating statin therapy. Nowhere near long enough to fairly evaluate statins benefit. 

http://www.thennt.com/nnt/statins-for-heart-disease-prevention-with-known-heart-disease/

This study shows some statin benefit for the different 3-point MACE metrics. However, it lacks information on baseline LDL-C level, baseline absolute risk of cardiovascular disease and magnitude of LDL-C reduction to adequately evaluate the 5 year risk reduction elicited by LDL-C lowering by statins.

http://www.thennt.com/nnt/statins-persons-low-risk-cardiovascular-disease/

Although I agree with its conclusion that persons of low cardiovascular disease risk likely experience little benefit of statin therapy, this example also lacks information on baseline LDL-C level and magnitude of LDL-C reduction to adequately evaluate the risk reduction elicited by LDL-C lowering by statins.